Stocktoria
IDEAYA Biosciences, Inc. IDYA
IDEAYA Biosciences, Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $218.7M | $7.0M | $23.4M | $50.9M | $27.9M | $19.5M | $0 | — |
| R&D expense | $314.7M | $294.7M | $129.5M | $89.5M | $58.2M | $39.7M | $34.3M | $31.7M |
| Operating income | -$159.3M | -$327.0M | -$134.4M | -$62.5M | -$50.3M | -$35.3M | -$44.3M | -$36.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$113.7M | -$274.5M | -$113.0M | -$58.7M | -$49.8M | -$34.5M | -$42.0M | -$34.3M |
| EPS (diluted) | $-1.28 | $-3.36 | $-1.96 | $-1.42 | $-1.41 | $-1.40 | — | — |
| Operating cash flow | -$71.1M | -$247.6M | -$115.2M | -$87.2M | -$55.8M | $55.5M | -$39.3M | -$27.6M |
| Free cash flow | -$73.5M | -$251.4M | -$117.6M | -$90.6M | -$58.4M | $55.0M | -$40.7M | -$29.3M |
| Cash & equivalents | $112.8M | $84.4M | $157.0M | $68.6M | $92.0M | $72.0M | $34.1M | $20.5M |
| Total assets | $1.1B | $1.1B | $649.3M | $388.0M | $381.3M | $298.3M | $113.0M | $96.5M |
| Total liabilities | $86.4M | $64.9M | $28.2M | $38.5M | $79.8M | $100.0M | $12.6M | $7.1M |
| Shareholders' equity | $1.0B | $1.1B | $621.1M | $349.5M | $301.5M | $198.3M | $100.4M | -$48.9M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | +3024.4% | -70.1% | -54.1% | +82.3% | +43.0% | — | — | — |
| Free cash flow growth | — | — | — | — | -206.3% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.